Mining real world data for drug development insights, Woodford-backed AI firm seeks $77M London IPO
Putting the words “artificial intelligence” near drug development these days is a sure way to generate buzz. But can it support a $77 million (£60 million) IPO haul in the UK? Former government minister and biotech entrepreneur Paul Drayson is set to find out.
At his firm, which has recently been renamed Sensyne Health, Drayson is combining his experience running a vaccine company and the science unit for the UK’s Department for Business, Innovation and Skills to build a business that promises to be useful for both clinicians and pharmaceutical partners.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.